Meeting
2022 ASCO Annual Meeting
Afatinib (Afa) + bevacizumab (Bev) versus afatinib alone as first-line treatment of patients with EGFR-mutated advanced non-squamous NSCLC: Primary analysis of the multicenter, randomized, phase II study—AfaBev-CS study.
Authors
Nobuhisa Ishikawa
Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan
Nobuhisa Ishikawa , Takashi Ninomiya , Toshiyuki Kozuki , Shoichi Kuyama , Koji Inoue , Toshihide Yokoyama , Nobuhiro Kanaji , Masayuki Yasugi , Takuo Shibayama , Keisuke Aoe , Nobuaki Ochi , Kazunori Fujitaka , Masahiro Kodani , Yutaka Ueda , Kazuhiko Watanabe , Akihiro Bessho , Keisuke Sugimoto , Isao Oze , Katsuyuki Kiura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
jRCTs061180006
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9112)
DOI
10.1200/JCO.2022.40.16_suppl.9112
Abstract #
9112
Poster Bd #
98
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2022 ASCO Annual Meeting
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
First Author: Hiroshige Yoshioka
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino